Cartesian regains Nasdaq minimum bid price compliance; delisting risk removed

Cartesian Therapeutics, Inc.

Received deficiency notice Jan 17, 2024 for bid price below $1.00 for 30 consecutive days.
Compliance period granted until July 15, 2024 to cure the deficiency.
On April 19, 2024, Nasdaq confirmed bid price ≥ $1.00 for 10 consecutive days from April 5-18.
Nasdaq considers the matter closed; company remains listed on Nasdaq Global Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.